For student doctors Genetic counselling is a structured clinical conversation that converts a family’s genetic concern into an understandable diagnosis, an evidence-based estimate of risk, and a safe plan. It is not simply giving a test result and it is not persuading a patient to accept one reproductive option. The counsellor combines clinical genetics, probability, communication, ethics and follow-up.
Learning outcomes
By the end of this chapter, you should be able to identify who needs referral; take a focused three-generation history; draw and interpret a pedigree; explain inheritance and recurrence risk; distinguish screening from diagnostic testing; obtain valid consent; disclose normal, positive, negative, uncertain and failed results; and support patient-centred decisions without coercion.
1. What genetic counselling means in clinical practice
Genetic counselling is the process of helping an individual or family understand the medical facts about a genetic condition, how heredity contributes, the probability that it may occur or recur, the choices for testing and management, and the psychosocial implications of each choice. The consultation should answer three questions: What is happening? What does it mean for this family? and What can we do next?
A good consultation separates facts from uncertainty. A diagnosis may be certain while the prognosis is variable; a screening result may indicate increased probability without proving disease; and a negative test may reduce risk without excluding every possible cause. State these distinctions explicitly so the family does not mistake reassurance for a guarantee or risk for a diagnosis.
Professional boundary: the doctor explains evidence, alternatives, likely outcomes and safety issues. The patient decides according to values, beliefs, family circumstances and the law. Avoid language such as “you should terminate” or “this result means the baby is abnormal.”
2. Who should be referred and why
Referral is appropriate whenever the diagnosis, inheritance pattern, recurrence risk or testing choice is not straightforward. It is especially important when a result may change pregnancy decisions, cancer surveillance, major surgery, reproductive planning or the testing of relatives.
| Referral trigger | Clinical reasoning | Immediate action |
|---|---|---|
| Known genetic disorder or pathogenic variant in the family | The familial variant may allow targeted, cheaper testing and more accurate risk calculation. | Obtain the relative’s laboratory report if possible; do not rely only on the family’s verbal label. |
| Previous child or pregnancy with a congenital anomaly, developmental disorder or unexplained death | The recurrence risk may be higher than background and the original diagnosis may be incomplete. | Collect records, photographs where appropriate, autopsy or neonatal notes and test results. |
| Three or more miscarriages, stillbirth, neonatal loss or severe unexplained illness | Chromosomal rearrangement, single-gene disease, thrombophilia or non-genetic causes may contribute. | Review obstetric chronology and refer for appropriate genetic and obstetric assessment. |
| Consanguinity or shared ancestry | Both partners may carry the same recessive allele; the risk depends on the pedigree and condition, not on stigma. | Ask neutrally about biological relatedness and offer carrier-risk assessment. |
| Abnormal ultrasound, serum screening or cell-free DNA screen | Screening changes probability; a diagnostic pathway is needed before irreversible decisions. | Confirm gestational age, explain residual risk and arrange specialist review. |
| Known teratogen, radiation or medication exposure | Outcome depends on agent, dose, timing, route and baseline risk; exposure alone is not a diagnosis. | Document exact dates and dose, then use an evidence-based teratology referral. |
| Personal or family pattern of early cancers | A germline cancer predisposition may affect surveillance and relatives. | Construct a cancer pedigree and discuss testing of an affected relative first when possible. |
3. Prepare before the patient arrives
Preparation prevents the consultation from becoming a rushed list of tests. Review the referral question, available records, pathology, imaging, laboratory reports and prior genetic tests. Check whether the laboratory used a test that can detect the suspected condition and whether the report describes a variant as pathogenic, likely pathogenic, uncertain, likely benign or benign.
Plan a private setting, enough time, an interpreter when needed and a support person chosen by the patient. Decide which diagrams or written summaries will make the explanation easier. For prenatal consultations, confirm gestational age, ultrasound findings, maternal medical history, blood group information where clinically relevant and the time available for results.
Pre-consultation safety check
- Is there an urgent pregnancy, neonatal or cancer-management decision?
- Could the result reveal non-paternity, adoption, consanguinity or another sensitive family fact?
- Who is legally able to consent for the test?
- What samples, laboratory services and referral pathways are realistically available?
- What will happen if the test is positive, negative, uncertain or fails?
4. The counselling consultation: a step-by-step method
Step 1 — Establish rapport, privacy and an agenda
Introduce yourself and your role. Confirm the patient’s preferred name, language and who may be present. Explain confidentiality and its limits. Start with an open question: “Please tell me what brought you here and what you most want us to answer today.” Reflect the concern before giving facts. Agree on an agenda, for example diagnosis, risk, testing, pregnancy options and follow-up.
Step 2 — Assess knowledge, expectations and emotion
Ask what the patient has already been told, what they think the result means and what they are afraid may happen. A patient may be asking for “a DNA test” when the real need is an explanation of a previous miscarriage or a child’s developmental delay. Acknowledge emotion without assuming the decision: “I can see this result is frightening; we can go through it one part at a time.”
Step 3 — Take a focused personal, obstetric and exposure history
Record diagnoses, age at onset, developmental milestones, dysmorphic features, seizures, hearing or visual impairment, chronic disease, surgeries, medications, miscarriages, stillbirths, neonatal deaths and fertility treatment. For pregnancy, document last menstrual period, gestational age, ultrasound findings, maternal illness, fever, diabetes, infections, alcohol, tobacco, prescribed and traditional medicines, radiation and occupational exposures. Ask the same questions of both partners when relevant.
Step 4 — Construct a three-generation pedigree
Use standard symbols: a square for a male, circle for a female, a horizontal line for a partnership, a vertical line for offspring, a diagonal slash for a deceased person and shading for the relevant condition. Record age or age at death, diagnosis, age at onset, biological relationships, miscarriages, stillbirths, infertility, consanguinity and country or ethnic background only when clinically relevant. Label the proband and date the pedigree.
Verify key diagnoses with records. “Heart problem” may mean a septal defect, cardiomyopathy or a non-genetic acquired disease; “mental retardation” should be replaced with the documented developmental diagnosis. Ask about unaffected relatives as well as affected ones because unaffected parents, skipped generations and male-to-male transmission help distinguish inheritance patterns.
Step 5 — Form a differential diagnosis
Combine phenotype, age of onset, pedigree and test results. Consider chromosomal, single-gene, mitochondrial, multifactorial, teratogenic and non-genetic explanations. A recognizable syndrome should prompt a targeted examination, but absence of classic features does not exclude it. Document what information is missing and what finding would change the working diagnosis.
Step 6 — Explain inheritance and calculate recurrence risk
Use absolute numbers and natural frequencies. For an autosomal dominant condition, a heterozygous affected parent has a one-in-two chance in each pregnancy, independent of previous children. For an autosomal recessive condition, two carrier parents have a one-in-four chance of an affected child, two-in-four chance of a carrier child and one-in-four chance of a child who is not a carrier. For an X-linked recessive condition, a carrier mother has a one-in-two chance of an affected son and a one-in-two chance of a carrier daughter, although new variants and skewed mechanisms can alter the simple pattern.
Explain that recurrence risk applies to each pregnancy; it is not a quota that becomes “used up.” If a patient has a one-in-four risk, four consecutive unaffected children do not make the next pregnancy automatically affected. Bayes’ theorem is useful when a test changes a prior risk: posterior odds equal prior odds multiplied by the likelihood ratio. In practice, show the starting risk, the test result and the remaining risk in a table.
| Example | Before testing | Test information | How to communicate after testing |
|---|---|---|---|
| Two known carriers of the same recessive disorder | 25% affected per pregnancy | Fetal diagnostic test identifies the familial variant | Explain whether the fetus is affected, a carrier or neither, and what the laboratory can and cannot exclude. |
| Maternal screening shows increased probability of trisomy 21 | Risk is higher than baseline, not a diagnosis | Offer diagnostic testing if the patient wants a definitive chromosome assessment | Use “increased chance” until diagnostic testing is available. |
| Unaffected relative asks about a familial dominant cancer variant | Risk depends on whether the affected parent carries the variant | Test the affected relative first when possible | Explain the difference between a familial negative and an uninformative negative. |
Step 7 — Discuss testing choices before taking a sample
Describe the purpose, sample, turnaround time, accuracy, possible findings, limitations, incidental findings, privacy, cost and what will happen after each result. Explain whether the test is targeted, a gene panel, chromosomal microarray, karyotype, exome or genome sequencing. A larger test may find more variants but also more uncertain findings and secondary information; “more genes” is not automatically better.
Step 8 — Obtain valid informed consent
Consent is a process, not a signature. Confirm that the patient understands the question, alternatives, possible results, implications for relatives, storage and future use of the sample, and the right to decline. Assess capacity, voluntariness and language. For children, explain assent when developmentally appropriate and obtain permission from the legally authorised decision-maker.
Step 9 — Communicate the result in a planned way
Arrange a visit or call with enough time for questions. Begin by asking what the patient remembers about the test. Give a warning shot, then the headline result, then the evidence and next steps. Pause. Avoid jargon such as “mutation” without explaining whether it is disease-causing. Use teach-back: “To make sure I explained it clearly, can you tell me what you understand the result to mean and what we will do next?”
Step 10 — Translate the result into management
Connect the result to surveillance, treatment, reproductive options, newborn planning, cascade testing and psychosocial support. Explain which recommendations are established and which are based on limited evidence. Make referrals and document who is responsible for follow-up; a result without a follow-up owner is an unsafe result.
5. How to explain common test results
Pathogenic or likely pathogenic
Explain the condition, penetrance, variable expression, inheritance, management and relatives who may benefit from testing. Clarify whether the result confirms the suspected diagnosis or explains only part of the phenotype.
Negative
State what was tested and what remains possible. A negative targeted test is reassuring only for the familial variant or method assessed; it may not exclude another gene, a structural variant, mosaicism or a non-genetic cause.
Variant of uncertain significance
Explain that current evidence cannot determine whether the variant is harmful. Do not use a VUS alone to make irreversible surgery, pregnancy or predictive-testing decisions. Reclassification may occur as evidence develops.
Test failed or is inconclusive
Possible reasons include inadequate sample, low fetal fraction, technical limits or a finding that needs confirmation. Discuss repeat sampling, an alternative method or specialist review without implying that failure itself means disease.
Never equate “no variant found” with “no genetic disease.” Always state the residual risk and the next diagnostic option if the clinical suspicion remains high.
6. Prenatal screening and diagnosis
Prenatal counselling begins with the patient’s goals and gestational age, not with a test catalogue. Explain that screening estimates probability while diagnosis examines fetal or placental material for a defined condition. The choice depends on the indication, time, procedure-related risk, available laboratory methods, cost and what the patient would do with each possible result.
| Approach | What it can contribute | Key limitations to explain |
|---|---|---|
| Ultrasound | Dating, growth, anatomy, fluid, placenta and markers of structural or chromosomal disease. | Normal anatomy does not exclude every genetic disorder; a marker is not a diagnosis; quality depends on gestation and expertise. |
| Maternal serum screening | Probability estimate for selected aneuploidies or open neural-tube defects depending on the panel. | False positives and false negatives occur; dating, maternal factors and multiple pregnancy affect performance. |
| Cell-free DNA screening | High-performance screening for selected common aneuploidies and sometimes sex-chromosome differences. | DNA is mainly placental; a positive result needs diagnostic confirmation; low fetal fraction and confined placental mosaicism can affect interpretation. |
| Chorionic villus sampling | Earlier placental sampling for karyotype, microarray or a known familial molecular test. | Invasive procedure; placental mosaicism can require amniocentesis for clarification; discuss local procedural risks. |
| Amniocentesis | Amniotic-fluid cells for chromosome, microarray and targeted molecular analysis. | Usually later than CVS; invasive; a normal result covers only the tests performed and does not exclude all anomalies. |
After an abnormal prenatal screen
First verify the report, gestational age and indication. Explain the result using “screen positive” or “increased chance,” not “the baby has.” Offer a detailed ultrasound and diagnostic confirmation where available. Discuss the time required for rapid aneuploidy testing, karyotype, microarray or a targeted familial test. Present continuation of pregnancy with monitoring and preparation, specialist treatment or palliative planning, adoption where relevant, and termination where lawful and consistent with the patient’s informed wishes. Do not delay urgent referral while debating values.
When a diagnostic result is abnormal
Explain the exact finding, expected range of severity, possibility of variable expression, available treatment and what remains uncertain. Offer a second opinion or specialist genetics review. Discuss the patient’s options neutrally, screen for distress or coercion, and record the information provided. A diagnosis describes biology; it does not determine the worth of the fetus or child.
7. Types and settings of counselling
Prospective counselling occurs before a condition or pregnancy outcome, for example carrier, preconception, predictive or cascade testing. Retrospective counselling follows an affected child, miscarriage, stillbirth or diagnosis and aims to explain what happened and the risk in future pregnancies. Pediatric counselling focuses on diagnosis, development, treatment and family support; predictive testing of a child should be justified by a childhood benefit. Adult and cancer counselling considers surveillance, reproductive implications, insurance or discrimination concerns, confidentiality and relatives.
Individual counselling protects privacy and allows tailored emotional support. Group education can efficiently explain basic genetics, but private risk assessment and consent still need an individual encounter. Non-directive counselling presents reasonable options and supports the patient’s values. Directive communication may be appropriate for immediate safety instructions, but it must not become pressure about reproductive choices.
8. A practical counselling script and checklist
- Open: “What is your main concern today, and what would you like us to decide or understand before you leave?”
- Check understanding: “What have you been told about the condition or screening result?”
- Map the family: draw the pedigree, verify diagnoses and ask permission before contacting relatives.
- Explain risk: use a diagram, natural frequencies and the patient’s own family example; separate baseline, test-adjusted and residual risk.
- Offer choices: explain what each test detects, what it cannot detect, possible results, time, cost, risks and alternatives.
- Explore values: “If the test showed the condition, what information would help you make a decision?” Never assume the answer.
- Close with teach-back: ask the patient to repeat the result, next step, warning signs and contact person.
- Document: indication, pedigree, risk estimate, options discussed, consent, decision, referrals and follow-up date.
Use short explanations followed by pauses. Avoid euphemisms, blame and unexplained percentages. If the patient becomes overwhelmed, provide a written summary and arrange a second visit rather than adding more facts. Invite a trusted support person only with the patient’s permission and use a trained interpreter rather than a child or untrained relative.
9. Common mistakes and how to correct them
| Mistake | Why it harms care | Correction |
|---|---|---|
| Starting with the test instead of the patient’s question | The test may not answer the real clinical problem. | Clarify the indication and desired decision first. |
| Using a single generic paragraph for every family | Risk, phenotype and values are family-specific. | Personalise the pedigree, probability and plan. |
| Calling a screen “positive diagnosis” | It can cause unnecessary fear or irreversible decisions. | Use “increased chance,” state PPV and offer confirmation. |
| Overpromising a negative result | Residual risk remains and surveillance may still be needed. | Name the tested genes/conditions and the limits of the method. |
| Treating a VUS as pathogenic | It may trigger inappropriate surgery or reproductive decisions. | Use phenotype and established guidance; await reclassification or seek expert review. |
| Ignoring relatives and confidentiality | Family members may miss preventive care or private information may be disclosed improperly. | Discuss cascade communication, consent and safe ways to share a family letter. |
10. Practical application in Uganda and other low-resource settings
Apply the same ethical and scientific standards even when specialist genetics services, laboratories, transport and funding are limited. Begin with a careful phenotype and pedigree, obtain copies of previous results, and contact an appropriate referral centre early when a result may affect pregnancy or cancer management. Do not promise a test or turnaround time that has not been confirmed. Explain costs and travel honestly, and consider whether a result will change management before ordering an expensive broad panel.
Where a test is unavailable, document the clinical diagnosis, provide prevention and surveillance that are appropriate, and create a plan for referral or later testing. Respect local languages, family structures and beliefs while correcting blame and stigma. A family should leave with a clear next step, a named contact and instructions for urgent symptoms or pregnancy changes.
11. Summary for examinations and ward practice
Genetic counselling is patient-centred risk communication. The core sequence is: clarify the question; take and verify a three-generation pedigree; establish or refine the diagnosis; determine inheritance and recurrence risk; explain screening, diagnosis and uncertainty; obtain informed consent; disclose results with teach-back; and connect the result to management, relatives and follow-up. Prenatal counselling must distinguish screening from diagnosis and present options without coercion. The quality of the consultation is measured not by how many tests were ordered, but by whether the patient understands the evidence and can make a voluntary, supported decision.
References and further reading
- NCBI Bookshelf: Genetic Counseling.
- NCBI Bookshelf: Genetic Testing and Assessment.
- SlideShare: Genetic Counselling — Advanced Nursing Practice (used as a teaching outline; verify against current clinical guidance).
- ACOG: Cell-free DNA screening.
- ISUOG clinical guidance and ultrasound resources.
